Evidence map›Paper›PMID 39082409›Full record

ArticleJournal of the American Heart Association2024

Trends in Primary Aldosteronism Screening Among High-Risk Hypertensive Adults.

Weerapat Kositanurit, John M Giacona, Donglu Xie, Jijia Wang, Daniel Feuer, Kyle J O'Malley, Ann Marie Navar, Anand Vaidya, Jordana B Cohen, Wanpen Vongpatanasin

Abstract readLetter
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weerapat KositanuritHypertension Section, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.
John M GiaconaHypertension Section, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.ORCID 0000-0003-0334-9876
Donglu XieInformation Resources-Research and Academic Systems University of Texas Southwestern Medical Center Dallas TX USA.
Jijia WangDepartment of Applied Clinical Research University of Texas Southwestern Medical Center Dallas TX USA.
Daniel FeuerUniversity of Texas Southwestern Medical School Dallas TX USA.
Kyle J O'MalleyUniversity of Texas Southwestern Medical School Dallas TX USA.
Ann Marie NavarCardiology Division, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.ORCID 0000-0002-6197-9860
Anand VaidyaCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension Brigham and Women's Hospital, Harvard Medical School Boston MA USA.ORCID 0000-0002-0314-9252
Jordana B CohenPerelman School of Medicine University of Pennsylvania Philadelphia PA USA.ORCID 0000-0003-4649-079X
Wanpen VongpatanasinHypertension Section, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.ORCID 0000-0002-7531-9388

Funding

Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral AdiposityR01HL159994 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Jarett D Berry, WANPEN VONGPATANASIN · 2022 to 2026
$4.0M
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 SurvivorsR01HL157108 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA, Jordana B. Cohen · 2022 to 2026
$3.9M
Multidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5M
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of lifeR01AG074989 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BRESS, ADAM P, COHEN, JORDANA B. · 2022 to 2025
$3.3M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical CentersU01HL160277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA · 2021 to 2026
$1.7M
NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL157108NHLBI NIH HHS R01 HL157264NHLBI NIH HHS R01 HL159994NHLBI NIH HHS U01 HL160277NIA NIH HHS R01 AG074989NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U24 DK060990
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HyperaldosteronismHypertensionMass ScreeningAdultAgedFemaleHumansMaleMiddle AgedRisk Factorsblood pressureCOVID‐19electronic health recordprimary aldosteronismresistant hypertension

Identifiers

PMID39082409
PMCPMC11964080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.